ABU DHABI, 5th June, 2023 (WAM) — The Department of Health – Abu Dhabi (DoH), the regulator of the healthcare sector in the Emirate, has signed a ‘Declaration of Collaboration’ with Eli Lilly Suisse S.A, a global healthcare leader, during their visit to the United States. The strategic cooperation seeks to establish a framework for collaboration on clinical research, real-world evidence and healthcare technology.
Witnessed by Mansoor Al Mansoori, Chairman of the Department of Health – Abu Dhabi (DoH) and Leigh Ann Pusey, Executive Vice President, Corporate Affairs and Communications at Eli Lilly, the Declaration of Collaboration was signed by Dr. Asma Al Mannaei, Executive Director of the Research and Innovation Center at the Department of Health – Abu Dhabi and Irina Zaporozhets, Vice President and General Manager Middle East at Eli Lilly.
In line with Abu Dhabi’s healthcare ambitions, both parties will drive clinical research and life science activities in the Emirate with focus on oncology, diabetes and neurological diseases. Furthermore, DoH and Eli Lilly will work together to explore innovations that address global healthcare challenges while leveraging Abu Dhabi’s evolving healthcare and life-science infrastructure and capabilities.
Through this collaboration, the Emirate seeks to initiate grand partnerships with leading global companies to exchange knowledge and expertise in line with international standards and best practices. Creating a transformative shift in the traditional healthcare paradigm in Abu Dhabi, the agreement contributes to the ongoing efforts to establish a competitive knowledge-based economy by unlocking the potential of the UAE’s national capabilities. In reflection of Abu Dhabi’s diverse ecosystem, DoH and Eli Lilly will explore the opportunity of cooperating in the field of health services and life-sciences to drive better healthcare outcomes locally and regionally.
In its essence, the agreement will expand Abu Dhabi’s footprint in life science research and development as well as enable innovation across all streams of healthcare and advanced therapeutics. The collaboration will aid in the acceleration of developing new treatments for diseases, improve healthcare outcomes and contribute to the health and well-being of the global community.
Dr. Asma said, “Through international collaborations, Abu Dhabi seeks to lead research groups supported by global partners to explore the resilience and sustainability of the healthcare sector worldwide as well as provide quality care to patients. Under the directives of our wise leadership, Abu Dhabi is paving the way for the region’s transformative journey through innovation, life science and valuable partnerships with global players in the field. The Department of Health – Abu Dhabi (DoH) is proud to partner with Eli Lilly to further improve healthcare outcomes while providing quality care and breakthrough treatments to patients in Abu Dhabi and beyond.”
Irina Zaporozhets said, “Our collaboration with the Department of Health – Abu Dhabi reflects Eli Lilly’s deep commitment to expanding access to our medicines and promoting innovation to improve the efficiency and effectiveness of healthcare delivery.” She added, “Since its establishment more than 145 years ago, Eli Lilly has been pursuing pharmaceutical innovation, providing high-quality products, and striving to deliver superior outcomes for patients all over the world. We take seriously our responsibility as partners in striving for innovation.”
Nicolas Chemali, Senior Vice President, International Market Access at Eli Lilly, confirmed, “We are proud to join hands with the Department of Health – Abu Dhabi, who plays a paramount role in the advancement of healthcare quality in Abu Dhabi and beyond.”
He added, “This collaboration paves the way for further cooperation to explore and establish innovations that addresses healthcare challenges and help make life better for people.”
The Department of Health – Abu Dhabi (DoH) leads a prominent delegation from Abu Dhabi on a visit to the USA from 1st to 8th June, 2023. The purpose of the visit is to showcase partnership opportunities and explore collaborations in Research and Development (R&D), manufacturing, and innovation.
Starting in Washington D.C., the delegates will engage with existing partners and forge new collaborations with governmental bodies and health-tech giants. The delegation will then conclude their mission in Boston, coinciding with Abu Dhabi's participation at BIO International Convention 2023, where they will showcase the Emirate's progress and development in the biotechnology industry. The participation will involve in-depth discussions, knowledge sharing, and exploring collaborations in health-tech, life sciences, and innovation.
Comprising 12 key entities including the DoH, Abu Dhabi Investment Office (ADIO), Etihad Cargo, KEZAD Group (part of AD Ports), Acino (part of ADQ), G42 Healthcare, M42, Mubadala Investment Company, Sheikh Shakhbout Medical City (SSMC), Pure Health, and Daman, the delegation represents the rich diversity and expertise within Abu Dhabi's ecosystem. With over 46 prominent stakeholders from diverse sectors, the delegation exemplifies the region's commitment to innovation, knowledge exchange, and international collaboration.
Abu Dhabi continues to work closely with global strategic partners to pave the way for a future driven by healthcare technology, innovation, and artificial intelligence as part of its transformation strategy to enhance healthcare outcomes. By collaborating with key global players in the biopharmaceutical industry, Abu Dhabi aims to strengthen local and global capabilities in life science, real-world evidence, digital health, and supply chain, solidifying its position as a leading healthcare destination.